169 related articles for article (PubMed ID: 38138247)
1. Afatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review.
Hong G
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138247
[TBL] [Abstract][Full Text] [Related]
2. [Hyponatremia in a 58-year-old female patient with EGFR-positive lung adenocarcinoma].
Koch M; Utpatel K; Schulz C
Internist (Berl); 2018 Apr; 59(4):384-387. PubMed ID: 28980030
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
Ikeuchi T; Tokuyasu H; Ishikawa S
Intern Med; 2019; 58(1):101-104. PubMed ID: 30606938
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report.
Cai Y; Wang X; Guo Y; Sun C; Xu Y; Qiu S; Ma K
Medicine (Baltimore); 2019 Jan; 98(1):e13890. PubMed ID: 30608413
[TBL] [Abstract][Full Text] [Related]
5. The effect of afatinib and radiotherapy on a patient with lung adenocarcinoma with a rare EGFR extracellular domain M277E mutation and high PD-L1 expression.
Lv D; Wang R; Wang X; Feng H
J Cancer Res Ther; 2022 Apr; 18(2):587-589. PubMed ID: 35645132
[TBL] [Abstract][Full Text] [Related]
6. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.
Fang YF; Liu PC
Thorac Cancer; 2021 Dec; 12(24):3429-3432. PubMed ID: 34729927
[TBL] [Abstract][Full Text] [Related]
7. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
Li SH; Hsieh MH; Fang YF
Medicine (Baltimore); 2015 Oct; 94(41):e1739. PubMed ID: 26469914
[TBL] [Abstract][Full Text] [Related]
8. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
Shi Y; Wang M
Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
10. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.
Liang SK; Ko JC; Yang JC; Shih JY
Lung Cancer; 2019 Jul; 133():103-109. PubMed ID: 31200815
[TBL] [Abstract][Full Text] [Related]
11. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer.
Oyama B; Morikawa K; Sakaguchi T; Tsunoda A; Kida H; Inoue T; Mineshita M
Intern Med; 2021; 60(3):441-444. PubMed ID: 33518612
[TBL] [Abstract][Full Text] [Related]
13. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
[No Abstract] [Full Text] [Related]
14. Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report.
Iida Y; Kumasawa F; Shimizu T; Shintani Y; Takahashi N; Gon Y
Thorac Cancer; 2020 Feb; 11(2):447-450. PubMed ID: 31779047
[TBL] [Abstract][Full Text] [Related]
15. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.
Wang XF; Zhao QT; Chen C
Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148
[No Abstract] [Full Text] [Related]
16. Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib: a case report.
Huang Q; Chen C; Hu S; Wu H; Yu D; Zhu X; Xue C; Wu Y; Tang J; Xie R; Ran F
Anticancer Drugs; 2022 Jan; 33(1):e730-e733. PubMed ID: 34387589
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
Zeng L; Xia C; Zhang Y; Yang N
J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
[No Abstract] [Full Text] [Related]
18. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
Jia Y; Ali SM; Saad S; Chan CA; Miller VA; Halmos B
Cancer Biol Ther; 2014 Aug; 15(8):970-4. PubMed ID: 24835218
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV; Yang JC; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater SL; Orlov S; Tsai CM; Boyer M; Su WC; Bennouna J; Kato T; Gorbunova V; Lee KH; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M
J Clin Oncol; 2013 Sep; 31(27):3327-34. PubMed ID: 23816960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
